InMed Pharmaceuticals Inc. (NASDAQ: INM) (‘InMed’ or the ‘Company’), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC (‘BayMedica’), a wholly owned subsidiary of the Company, in light of ongoing uncertainty surrounding U.S. federal…
The Government of New Brunswick announced a new comprehensive mineral strategy on Tuesday (March 3), at the 2026 Prospectors…
Adrian Day, president of Adrian Day Asset Management, shares his latest thoughts on what’s moving the gold price, emphasizing…
Brien Lundin, editor of Gold Newsletter and New Orleans Investment Conference host, shares his stock-picking strategy at a time…
Peter Krauth, editor of Silver Stock Investor and Silver Advisor, shares his thoughts on silver price activity and where…
Chen Lin of Lin Asset Management weighs in on silver and gold, as well as the critical minerals market,…
Alvopetro Energy Ltd. (TSXV: ALV,OTC:ALVOF) (OTCQX: ALVOF) announces February sales volumes of 3,058 boepd (based on field estimates), a…